MAP2K5 and carcinoma: Particularly, in high-grade carcinomas, ERK5 immunoreactivity demonstrated both cytoplasmic and nuclear patterns, while in benign prostate tissue, ERK5 signals resulted exclusively cytoplasmic, in keeping with activation of the MEK5/ERK5 pathway in PCa [150].